Literature DB >> 11520751

Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.

J M Ruiz-Moreno1, C de la Vega.   

Abstract

AIM: To analyse the visual results obtained in the treatment of subretinal choroidal neovascularisation (CNV) in patients with high myopia by vitrectomy and extraction of the neovascular membrane.
METHODS: 22 eyes of 22 patients with high myopia (>-6 dioptres and/or axial length >26 mm) with subfoveal CNV treated by extraction of the CNV were analysed retrospectively. The patients' mean age was 60.27 (SD 16.41) years (range 32-83 years). The mean follow up was 29.3 (9.9) months (range 12-42 months).
RESULTS: Best corrected visual acuity (BCVA) preoperatively was 0.09 (0.07) (range 0.01-0.3). After treatment BCVA was 0.12 (0.10) (range 0.01-0.4), a difference without statistical significance (p=0.03, Student's t test paired data). In four cases the CNV recurred, in three cases cataract developed that required extraction, and in one case retinal detachment occurred in the early postoperative period. Topical treatment was necessary in two cases to lower the intraocular pressure.
CONCLUSIONS: The treatment of subfoveal CNV in highly myopic patients by surgical removal by vitrectomy does not achieve any significant improvement of the BCVA.

Entities:  

Mesh:

Year:  2001        PMID: 11520751      PMCID: PMC1724121          DOI: 10.1136/bjo.85.9.1041

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  Pathologic findings in pathologic myopia.

Authors:  H E Grossniklaus; W R Green
Journal:  Retina       Date:  1992       Impact factor: 4.256

2.  Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration.

Authors:  E de Juan; R Machemer
Journal:  Am J Ophthalmol       Date:  1988-01-15       Impact factor: 5.258

3.  Axial length measurements and fundus changes of the myopic eye.

Authors:  B J Curtin; D B Karlin
Journal:  Am J Ophthalmol       Date:  1971-01       Impact factor: 5.258

4.  Surgical removal of subfoveal choroidal neovascular membranes in high myopia.

Authors:  F Bottoni; E Perego; P Airaghi; M Cigada; S Ortolina; G Carlevaro; V De Molfetta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-07       Impact factor: 3.117

5.  Subretinal surgery for choroidal neovascularization in patients with high myopia.

Authors:  A Uemura; M A Thomas
Journal:  Arch Ophthalmol       Date:  2000-03

6.  Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia.

Authors:  R Brancato; A Pece; P Avanza; E Radrizzani
Journal:  Retina       Date:  1990       Impact factor: 4.256

7.  Natural history of choroidal neovascularization in degenerative myopia.

Authors:  M P Avila; J J Weiter; A E Jalkh; C L Trempe; R C Pruett; C L Schepens
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

8.  Visual prognosis of disciform degeneration in myopia.

Authors:  G R Hampton; D Kohen; A C Bird
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

Review 9.  Physiologic vs pathologic myopia: genetics vs environment.

Authors:  B J Curtin
Journal:  Ophthalmology       Date:  1979-05       Impact factor: 12.079

10.  Visual results after surgical removal of subfoveal choroidal neovascular membranes.

Authors:  M A Thomas; J D Dickinson; N S Melberg; H E Ibanez; R S Dhaliwal
Journal:  Ophthalmology       Date:  1994-08       Impact factor: 12.079

View more
  17 in total

1.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

Review 2.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

3.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

4.  Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV.

Authors:  Sengul Ozdek; Ahmet Hondur; Gokhan Gurelik; Berati Hasanreisoglu
Journal:  Int Ophthalmol       Date:  2006-11-16       Impact factor: 2.031

5.  Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.

Authors:  Izumi Yamamoto; Adam H Rogers; Elias Reichel; Paul A Yates; Jay S Duker
Journal:  Br J Ophthalmol       Date:  2006-07-26       Impact factor: 4.638

6.  Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.

Authors:  H Sakaguchi; Y Ikuno; F Gomi; M Kamei; M Sawa; M Tsujikawa; Y Oshima; S Kusaka; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-16       Impact factor: 4.638

Review 7.  Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Authors:  Ying Zhu; Ting Zhang; Gezhi Xu; Lijun Peng
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

8.  Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study.

Authors:  R Hera; C Chiquet; J P Romanet
Journal:  Int Ophthalmol       Date:  2013-03-29       Impact factor: 2.031

9.  Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-29       Impact factor: 3.117

10.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.

Authors:  D S C Lam; W-M Chan; D T L Liu; D S P Fan; W W Lai; K K L Chong
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.